Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
DVAX

DVAX - Dynavax Technologies Corp Stock Price, Fair Value and News

$15.480.00 (0.00%)
Market Closed

23/100

DVAX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

23/100

DVAX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$12.41

Target 3M

$14.07

Target 6M

$13.18

DVAX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DVAX Price Action

Last 7 days

-1.3%

Last 30 days

0.7%

Last 90 days

48.9%

Trailing 12 Months

19.6%

DVAX RSI Chart

DVAX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DVAX Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-41.88

Price/Sales (Trailing)

5.5

EV/EBITDA

-53.63

Price/Free Cashflow

22.57

DVAX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$12.41

Target 3M

$14.07

Target 6M

$13.18

DVAX Fundamentals

DVAX Revenue

Revenue (TTM)

330.5M

Rev. Growth (Yr)

17.67%

Rev. Growth (Qtr)

-0.59%

DVAX Earnings

Earnings (TTM)

-43.4M

Earnings Growth (Yr)

53.05%

Earnings Growth (Qtr)

43.83%

DVAX Profitability

EBT Margin

-12.29%

Return on Equity

-8.13%

Return on Assets

-4.59%

Free Cashflow Yield

4.43%

DVAX Investor Care

Buy Backs (1Y)

10.67%

Diluted EPS (TTM)

-0.36

DVAX Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025294.6M316.3M330.5M0
2024236.1M249.7M260.8M277.2M
2023655.6M459.4M361.2M232.3M
2022470.1M673.8M733.3M722.7M
2021119.0M169.1M263.9M439.4M
202040.4M34.7M37.6M46.6M
201913.8M20.9M30.0M35.2M
2018344.0K1.5M2.9M8.2M
20178.4M5.7M3.0M327.0K
20164.4M5.5M4.4M11.0M
20158.2M6.7M5.6M4.0M
201412.7M12.3M11.6M11.0M
201310.1M10.5M10.9M11.3M
20120009.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Dynavax Technologies Corp

DVAX
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
 CEO
 WEBSITEdynavax.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES351

Dynavax Technologies Corp Frequently Asked Questions

DVAX is the stock ticker symbol of Dynavax Technologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Dynavax Technologies Corp is 1.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check DVAX's fair value in chart for subscribers.

The fair value guage provides a quick view whether DVAX is over valued or under valued. Whether Dynavax Technologies Corp is cheap or expensive depends on the assumptions which impact Dynavax Technologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DVAX.

As of Wed Jan 28 2026, DVAX's PE ratio (Price to Earnings) is -41.88 and Price to Sales (PS) ratio is 5.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DVAX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Dynavax Technologies Corp has provided -0.043 (multiply by 100 for percentage) rate of return.